Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Zacks: Analysts Anticipate Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to Announce $4.05 EPS

researchsnappy by researchsnappy
January 2, 2020
in Healthcare Research
0
Zacks: Analysts Anticipate Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to Announce $4.05 EPS
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Jazz Pharmaceuticals logoBrokerages expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to announce earnings of $4.05 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Jazz Pharmaceuticals’ earnings. The highest EPS estimate is $4.17 and the lowest is $3.84. Jazz Pharmaceuticals reported earnings of $3.64 per share in the same quarter last year, which would suggest a positive year over year growth rate of 11.3%. The firm is expected to issue its next earnings results on Tuesday, February 25th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $15.86 per share for the current financial year, with EPS estimates ranging from $15.66 to $16.00. For the next fiscal year, analysts forecast that the firm will report earnings of $17.59 per share, with EPS estimates ranging from $15.57 to $19.45. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The business had revenue of $537.70 million for the quarter, compared to analysts’ expectations of $523.92 million. During the same quarter in the previous year, the business posted $3.58 earnings per share. The business’s revenue was up 14.6% compared to the same quarter last year.

A number of research analysts have weighed in on JAZZ shares. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, November 29th. Barclays boosted their target price on shares of Jazz Pharmaceuticals from $182.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. BidaskClub lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 target price for the company. in a research note on Friday, September 13th. Finally, Wells Fargo & Co boosted their target price on shares of Jazz Pharmaceuticals from $168.00 to $186.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $168.71.

JAZZ stock traded up $0.63 during mid-day trading on Wednesday, reaching $149.28. 253,631 shares of the stock traded hands, compared to its average volume of 442,334. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.71 and a current ratio of 3.89. Jazz Pharmaceuticals has a one year low of $116.52 and a one year high of $154.24. The stock has a market capitalization of $8.44 billion, a PE ratio of 12.20, a PEG ratio of 0.93 and a beta of 1.15. The business has a 50-day moving average price of $147.49 and a two-hundred day moving average price of $135.28.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 10,750 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $150.00, for a total value of $1,612,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Patricia Carr sold 1,749 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $148.93, for a total transaction of $260,478.57. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,249 shares of company stock valued at $3,159,444. 4.30% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its holdings in Jazz Pharmaceuticals by 28.2% in the second quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock worth $364,355,000 after purchasing an additional 562,700 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in Jazz Pharmaceuticals by 4,979.1% in the second quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock worth $274,324,000 after purchasing an additional 1,886,384 shares in the last quarter. Boston Partners raised its holdings in Jazz Pharmaceuticals by 1.8% in the third quarter. Boston Partners now owns 1,364,882 shares of the specialty pharmaceutical company’s stock worth $174,887,000 after purchasing an additional 23,859 shares in the last quarter. LSV Asset Management raised its holdings in Jazz Pharmaceuticals by 12.5% in the second quarter. LSV Asset Management now owns 1,127,120 shares of the specialty pharmaceutical company’s stock worth $160,682,000 after purchasing an additional 125,470 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Jazz Pharmaceuticals by 46.9% in the second quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock worth $147,496,000 after purchasing an additional 337,396 shares in the last quarter. Institutional investors and hedge funds own 89.16% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: How to calculate the annual rate of depreciation

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Different transmission routes and the risk of advanced HIV disease: A systematic review and network meta-analysis of observational studies

Next Post

New state law bans pubic funding for human cloning

Next Post
New state law bans pubic funding for human cloning

New state law bans pubic funding for human cloning

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

3 Best Market Research Certifications in High Demand

PRC needs full funding to do its job | My View

Plant-based Chicken Market 2021 by Global Key Players, Types, Applications, Countries, Industry Size and Forecast to 2030 – Energy Siren

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2023 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2023 researchsnappy.com